Articles

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia

University of Texas, MD Anderson Cancer Center, Houston, TX, USA
University of Michigan, Ann Arbor, MI, USA
Tufts Medical Center, Boston, MA, USA
City of Hope Cancer Center, Duarte, CA, USA
Winship Cancer Institute of Emory University, Atlanta, GA, USA
University of Texas, MD Anderson Cancer Center, Houston, TX, USA
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
University of Chicago, IL, USA
Mitchell Pharmaceutical Consulting, Lafayette, CO, USA
Deciphera Pharmaceuticals LLC, Waltham, MA, USA
Deciphera Pharmaceuticals LLC, Waltham, MA, USA
Deciphera Pharmaceuticals LLC, Waltham, MA, USA
Deciphera Pharmaceuticals LLC, Waltham, MA, USA
University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Deciphera Pharmaceuticals LLC, Waltham, MA, USA
UC Irvine Chao Family Comprehensive Cancer Center, Orange, CA, USA
Vol. 102 No. 3 (2017): March, 2017 https://doi.org/10.3324/haematol.2016.152710